Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Finished Goods (2022 - 2025)

Arcutis Biotherapeutics has reported Finished Goods over the past 4 years, most recently at $12.6 million for Q4 2025.

  • Quarterly results put Finished Goods at $12.6 million for Q4 2025, up 30.2% from a year ago — trailing twelve months through Dec 2025 was $12.6 million (up 30.2% YoY), and the annual figure for FY2025 was $12.6 million, up 30.2%.
  • Finished Goods for Q4 2025 was $12.6 million at Arcutis Biotherapeutics, up from $11.6 million in the prior quarter.
  • Over the last five years, Finished Goods for ARQT hit a ceiling of $12.6 million in Q4 2025 and a floor of $698000.0 in Q3 2022.
  • Median Finished Goods over the past 4 years was $4.3 million (2024), compared with a mean of $5.5 million.
  • Biggest five-year swings in Finished Goods: skyrocketed 257.51% in 2024 and later surged 30.2% in 2025.
  • Arcutis Biotherapeutics' Finished Goods stood at $1.5 million in 2022, then soared by 84.73% to $2.7 million in 2023, then skyrocketed by 257.51% to $9.6 million in 2024, then soared by 30.2% to $12.6 million in 2025.
  • The last three reported values for Finished Goods were $12.6 million (Q4 2025), $11.6 million (Q3 2025), and $7.9 million (Q2 2025) per Business Quant data.